Temperature Excursions in Clinical Supply: A Practical Response Playbook

A temperature excursion is any departure from a product's labeled storage conditions — the moment a 2–8°C shipment logs 10.4°C for ninety minutes on an airport tarmac. Excursions are not rare events to be embarrassed about; they are a statistical certainty of global distribution. What separates well-run supply chains from chaotic ones is not zero excursions — it's a fast, pre-built response process that protects patients, preserves product, and keeps sites dosing.

What should happen in the first 24 hours after an excursion?

Three moves, in order. Quarantine first: the affected product is segregated and status-flagged — in the IRT, at the depot, or at the site — so it cannot be dispensed while under review. Capture the data: the complete logger download (not a summary), excursion duration, peak/trough temperatures, and the product's prior excursion history, because stability budgets are cumulative — a shipment that survived one excursion has spent part of its allowance. Notify per the escalation path: site or depot to sponsor quality, with a defined turnaround expectation.

The single biggest operational failure we see isn't the excursion itself; it's product sitting in quarantine for weeks because nobody owns the next step while a site runs out of stock.

Who decides whether the product is still usable?

Disposition is a quality decision informed by stability science — typically the sponsor's quality unit, drawing on the product's stability data and, where established, its allowable excursion budget: the documented time-out-of-refrigeration or time-above-limit the molecule can tolerate based on stability studies.

Mature programs pre-negotiate disposition rules ("excursions to ≤15°C for ≤24 hours cumulative: acceptable; release and log against the budget") so that the majority of routine excursions resolve in hours via a lookup table rather than weeks via an ad hoc scientific review. The ad hoc route should be reserved for the excursions that genuinely exceed the pre-assessed envelope.

How do excursions differ across the lanes of a trial?

Each lane fails differently, so each needs its own playbook page:

• Depot-to-depot lanes fail at customs and cargo handling — long, documented, usually recoverable.
• Depot-to-site lanes fail at receipt: the box that sits unopened over a weekend. Site processes (immediate logger check-in, receipt SOPs) prevent more losses than better shippers do.
• Site storage failures — the pharmacy refrigerator that drifts overnight — are the quiet giant, often affecting far more product than any single shipment; continuous monitoring with alarming, not daily manual logs, is the fix.
• Direct-to-patient lanes add the porch and the patient's refrigerator; excursion response there must include patient-facing instructions and a pre-defined replacement-dose pathway so dosing continuity survives a failed delivery.

What actually prevents excursions — versus paperwork that just documents them?

Prevention concentrates in four investments: lane qualification with seasonal profiles (the same lane behaves differently in August and January); shipper selection matched to duration risk, with the honest math that a more expensive shipper is cheaper than one lost shipment of biologic; receipt discipline at sites, trained and verified, because the last meter is where good lanes go to die; and trend review — excursion data analyzed quarterly by lane, courier, season, and site, so the supply chain learns.

A file of perfectly documented, endlessly repeated excursions is compliance theater. A declining excursion trend line is management.